Ain’t That A Sham: US House Bill Tries To Thread The Needle On Citizen Petitions
For years, brand industry critics have decried the use of “sham” citizen petitions to delay generic drug approvals. But one person’s “sham” is another person’s First Amendment right to petition the government. A House bill tries to thread that needle.
You may also be interested in...
US committee will likely re-examine the language regarding the burden of proof in a bill prohibiting pay-for-delay settlements.
Indictment alleges Indivior falsely cited concerns about pediatric exposure to tablets in discontinuing the formulation; FDA official says company tried to mislead agency and bar competition for Suboxone.
Updated numbers from the US FDA's REMS abuse website show that Celgene has received two additional safety determination letters, raising question's about whether the public list has changed the practices of brand companies hindering generic company access to samples.